Φορτώνει......
CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
Parkinson's disease (PD) is a neurodegenerative disorder for which only symptomatic treatments are available. Repurposing drugs that target α-synuclein aggregation, considered one of the main drivers of PD progression, could accelerate the development of disease-modifying therapies. In this wor...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Sci Rep |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Nature Publishing Group UK
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7679368/ https://ncbi.nlm.nih.gov/pubmed/33219264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-76927-0 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|